As of Wednesday close, Assembly Biosciences Inc.’s (NASDAQ:ASMB) stock was down -$0.08, moving down -5.59 percent to $1.35. The average number of shares traded per day over the past five days has been 253,420 shares. 4 times new highs have been achieved over the past 5 days, with a $0.0300 gain in that time frame. In the last twenty days, the average volume was 234,950, while in the previous 50 days, it was 216,406.
Since last month, ASMB stock retreated -16.15%. Shares of the company fell to $1.2000 on 11/09/22, the lowest level in the past month. A 52-week high of $2.45 was reached on 01/03/22 after having rallying from a 52-week low of $1.20. Since the beginning of this year, ASMB’s stock price has dropped by -42.06% or -$0.9800, and marked a new high 1 time. However, the stock has declined by -44.90% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
ASMB stock investors should be aware that Assembly Biosciences Inc. (ASMB) stock had its last reported insider trading activity 108 days ago on Aug 08. McHutchison John G, the Chief Executive Officer of the company, disposed of 12,314 shares for $2.13 on Aug 08. It resulted in a $26,200 divestment by the insider. Samar Michael P. sold 2,020 shares at an average price of $2.22 on Jul 25. The insider now owns 77,228 shares following the transaction. On May 31, Chief Scientific Officer Delaney William E IV sold 4,164 shares at $1.92 apiece. The transaction was valued at $8,005.
In the three months ended September 29, Assembly Biosciences Inc.’s quick ratio stood at 7.40, while its current ratio was 7.40, showing that the company is able to pay off its debt. Based on annual data, ASMB earned $138.94 million in gross profit and brought in $6.25 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -77.10%. Return on equity (ROE) for the past 12 months was -96.60%.
While analysts expected Assembly Biosciences Inc. to report -$0.47 quarterly earnings, the actual figure was -$0.48 per share, beating the consensus estimate by -2.10%. During the quarter, the company generated -$23.25 million in EBITDA. The liabilities of Assembly Biosciences Inc. were 19.11 million at the end of its most recent quarter ended September 29, and its total debt was $4.29 million. The value of shareholders’ equity is $48.78 million.
This quick technical analysis looks at Assembly Biosciences Inc.’s (ASMB) price momentum. With a historical volatility rate of 72.16%, the RSI 9-day stood at 39.94% on 23 November.
With respect to its five-day moving average, the current Assembly Biosciences Inc. price is up by +2.27% percent or $0.0300. At present, ASMB shares trade -19.64% below its 20-day simple moving average and -37.21% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.78% below its SMA50 and -19.16% below its SMA200.
Stochastic coefficient K was 43.34% and Stochastic coefficient D was 40.44%, while ATR was 0.1023. Given the Stochastic reading of 34.88% for the 14-day period, the RSI (14) reading has been calculated as 39.09%. As of today, the MACD Oscillator reading stands at 0.0167.
H.C. Wainwright launched its rating on Assembly Biosciences Inc. (NASDAQ: ASMB) to a Neutral in a note to investors on September 13, 2021. Assembly Biosciences Inc. (ASMB) has been rated Overweight by analysts. According to 0 brokerage firms, ASMB is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Assembly Biosciences Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $2.50, the current consensus forecast for the stock is $2.00 – $3.00. Based on these forecasts, analysts predict Assembly Biosciences Inc. (ASMB) will achieve an average price target of $2.50.